Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H21ClFN3O4S |
| Molecular Weight | 441.904 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(F)C=CC=C1NC(=O)NC2=CC=C(Cl)C(=C2O)S(=O)(=O)[C@H]3CCCNC3
InChI
InChIKey=NGYNBSHYFOFVLS-LBPRGKRZSA-N
InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1
| Molecular Formula | C19H21ClFN3O4S |
| Molecular Weight | 441.904 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Danixirin is a potent, competitive, selective and reversible antagonist of the chemokine receptor (CXCR2) (also known as interleukin 8B receptor). In preclinical models, danixirin blocked neutrophils chemotaxis in response to inflammation. The drug is being developed by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease, influenza, respiratory syncytial virus. In phase 2 clinical trials in patients with acute, uncomplicated influenza, danixirin was well tolerated and did not impede viral clearance.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:40:40 UTC 2023
by
admin
on
Fri Dec 15 19:40:40 UTC 2023
|
| Record UNII |
R318PGH5VP
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
954126-98-8
Created by
admin on Fri Dec 15 19:40:40 UTC 2023 , Edited by admin on Fri Dec 15 19:40:40 UTC 2023
|
PRIMARY | |||
|
C169874
Created by
admin on Fri Dec 15 19:40:40 UTC 2023 , Edited by admin on Fri Dec 15 19:40:40 UTC 2023
|
PRIMARY | |||
|
9559
Created by
admin on Fri Dec 15 19:40:40 UTC 2023 , Edited by admin on Fri Dec 15 19:40:40 UTC 2023
|
PRIMARY | |||
|
100000166272
Created by
admin on Fri Dec 15 19:40:40 UTC 2023 , Edited by admin on Fri Dec 15 19:40:40 UTC 2023
|
PRIMARY | |||
|
R318PGH5VP
Created by
admin on Fri Dec 15 19:40:40 UTC 2023 , Edited by admin on Fri Dec 15 19:40:40 UTC 2023
|
PRIMARY | |||
|
SUB180340
Created by
admin on Fri Dec 15 19:40:40 UTC 2023 , Edited by admin on Fri Dec 15 19:40:40 UTC 2023
|
PRIMARY | |||
|
24780598
Created by
admin on Fri Dec 15 19:40:40 UTC 2023 , Edited by admin on Fri Dec 15 19:40:40 UTC 2023
|
PRIMARY | |||
|
DB11922
Created by
admin on Fri Dec 15 19:40:40 UTC 2023 , Edited by admin on Fri Dec 15 19:40:40 UTC 2023
|
PRIMARY | |||
|
CHEMBL3039531
Created by
admin on Fri Dec 15 19:40:40 UTC 2023 , Edited by admin on Fri Dec 15 19:40:40 UTC 2023
|
PRIMARY | |||
|
YY-70
Created by
admin on Fri Dec 15 19:40:40 UTC 2023 , Edited by admin on Fri Dec 15 19:40:40 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
